Rabies infection - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 hours
DelveInsight’s, “Rabies infection – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Rabies infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Rabies infection: Overview
Rabies is a viral zoonotic disease that is transmitted to human beings through the bite of rabid animals. The virus predominantly infects the central nervous system leading to progressive and fatal inflammation of brain and spinal cord. Rabies is caused by a lyssavirus (a form of virus that causes encephalitis) that affects the saliva and nervous system. Most cases of rabies in humans are caused by a bite or scratch from an infected animal. It is possible, but rare, for people to get rabies if infectious material from a rabid animal, such as saliva, gets directly into their eyes, nose, mouth, or a wound. Rabies is estimated to cause death of more than 59,000 individuals over 150 countries across the globe with most of the cases in Africa, and Asia. Rabies infection cannot be diagnosed easily as there is no usual way to confirm rabies transmission at the time of bite. Therefore, prophylactic treatment is initiated without waiting for confirm diagnosis. If left untreated may lead to coma or death. Medical assistance should be obtained as soon as possible after an exposure or possible exposure to rabies. The most effective treatment for rabies is immediate treatment of the wound followed by immunization with the rabies vaccine.
'Rabies infection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rabies infection pipeline landscape is provided which includes the disease overview and Rabies infection treatment guidelines. The assessment part of the report embraces, in depth Rabies infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rabies infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Rabies infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rabies infection Emerging Drugs
Further product details are provided in the report.
Rabies infection: Therapeutic Assessment
This segment of the report provides insights about the different Rabies infection drugs segregated based on following parameters that define the scope of the report, such as:
Rabies infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rabies infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rabies infection drugs.
Rabies infection Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Rabies infection – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Rabies infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Rabies infection: Overview
Rabies is a viral zoonotic disease that is transmitted to human beings through the bite of rabid animals. The virus predominantly infects the central nervous system leading to progressive and fatal inflammation of brain and spinal cord. Rabies is caused by a lyssavirus (a form of virus that causes encephalitis) that affects the saliva and nervous system. Most cases of rabies in humans are caused by a bite or scratch from an infected animal. It is possible, but rare, for people to get rabies if infectious material from a rabid animal, such as saliva, gets directly into their eyes, nose, mouth, or a wound. Rabies is estimated to cause death of more than 59,000 individuals over 150 countries across the globe with most of the cases in Africa, and Asia. Rabies infection cannot be diagnosed easily as there is no usual way to confirm rabies transmission at the time of bite. Therefore, prophylactic treatment is initiated without waiting for confirm diagnosis. If left untreated may lead to coma or death. Medical assistance should be obtained as soon as possible after an exposure or possible exposure to rabies. The most effective treatment for rabies is immediate treatment of the wound followed by immunization with the rabies vaccine.
'Rabies infection - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rabies infection pipeline landscape is provided which includes the disease overview and Rabies infection treatment guidelines. The assessment part of the report embraces, in depth Rabies infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rabies infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Rabies infection R&D. The therapies under development are focused on novel approaches to treat/improve Rabies infection.
This segment of the Rabies infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Rabies infection Emerging Drugs
- SYN-023: Synermore Biologics
- Freeze-dried human rabies vaccine: Anhui Zhifei Longcom Biopharmaceutical
Further product details are provided in the report.
Rabies infection: Therapeutic Assessment
This segment of the report provides insights about the different Rabies infection drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Rabies infection
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Rabies infection: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rabies infection therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rabies infection drugs.
Rabies infection Report Insights
- Rabies infection Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Rabies infection drugs?
- How many Rabies infection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rabies infection?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rabies infection therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Rabies infection and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Rabies infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
SYN-023: Synermore Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
PIKA Rabies vaccine - Yisheng Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical stage products
Comparative Analysis
IMT 504: Connectyx Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Rabies infection Key Companies
Rabies infection Key Products
Rabies infection- Unmet Needs
Rabies infection- Market Drivers and Barriers
Rabies infection- Future Perspectives and Conclusion
Rabies infection Analyst Views
Rabies infection Key Companies
Appendix
Executive Summary
Rabies infection: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
SYN-023: Synermore Biologics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Mid Stage Products (Phase II)
Comparative Analysis
PIKA Rabies vaccine - Yisheng Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Preclinical stage products
Comparative Analysis
IMT 504: Connectyx Technologies
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Rabies infection Key Companies
Rabies infection Key Products
Rabies infection- Unmet Needs
Rabies infection- Market Drivers and Barriers
Rabies infection- Future Perspectives and Conclusion
Rabies infection Analyst Views
Rabies infection Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Rabies infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Rabies infection
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Rabies infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Rabies infection
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products